Temozolomide reconsidered: Real-World evidence in resistant melanoma cases

Area of Science:

• Oncology
• Immunotherapy
• Cancer Treatment

Background:

• Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but subsequent treatment options are limited.
• Limited efficacy, cost, and patient health often restrict choices after ICI failure.
• Temozolomide is being reconsidered as a potential bridge therapy, especially with anti-PD-1 agents.

Purpose of the Study:

• To report two cases of single-agent temozolomide as a subsequent therapy.
• To assess clinical response and tolerability in patients progressing on prior systemic therapies including ICIs.
• To explore the role of temozolomide in modern cancer treatment sequencing.

Main Methods:

• Case report of two patients with advanced malignancies.
• Patients received single-agent temozolomide after disease progression on prior systemic treatments.
• Prior treatments included anti-PD-1 therapy and, in one case, targeted therapy.

Main Results:

• Both patients demonstrated meaningful clinical responses to temozolomide.
• Temozolomide was well-tolerated in both cases.
• These findings suggest potential synergistic activity and tolerability.

Conclusions:

• Single-agent temozolomide can be an effective and tolerable subsequent therapy after progression on ICIs.
• These cases support further investigation of temozolomide in contemporary cancer treatment strategies.
• Temozolomide may offer a viable option when other treatments are exhausted.